



June 2024

Clinical Criteria Updates Effective September 10, 2024

Please note, this communication applies to Healthy Blue + MedicareSM (HMO-POS D-SNP) offered by Blue Cross and Blue Shield of North Carolina (Blue Cross NC).

Summary: On May 19, 2023, August 18, 2023, November 17, 2023, December 11, 2023, and February 23, 2024, the Pharmacy and Therapeutic (P&T) Committee approved the following *Clinical Criteria* applicable to the medical drug benefit for *Blue Cross NC*. These policies were developed, revised, or reviewed to support clinical coding edits.

Visit [Clinical Criteria](#) to search for specific policies. For questions or additional information, use this [email](#).

Please see the explanation/definition for each category of *Clinical Criteria* below:

- New: newly published criteria
- Revised: addition or removal of medical necessity requirements, new document number
- Updates marked with an asterisk (*) notate that the criteria may be perceived as more restrictive

Please share this notice with other providers in your practice and office staff.

Please note:

- **The *Clinical Criteria* listed below applies only to the medical drug benefits contained within the member’s medical policy. This does not apply to pharmacy services.**
- **This notice is meant to inform the provider of new or revised criteria that has been adopted by *Blue Cross NC* only. It does not include details regarding any authorization requirements. Authorization rules are communicated via a separate notice.**

Effective Date	Clinical Criteria Number	Clinical Criteria Title	New or Revised
September 10, 2024	*CC-0258	iDoseTR (travoprost Implant)	New
September 10, 2024	*CC-0259	Amtagvi (lifleucel)	New

<https://www.bluecrossnc.com/providers/networks-programs/blue-medicare/healthy-blue-medicare>

Blue Cross and Blue Shield of North Carolina Senior Health, DBA Blue Cross and Blue Shield of North Carolina, is an HMO-POS D-SNP plan with a Medicare contract and a NC State Medicaid Agency Contract (SMAC). Enrollment in Blue Cross and Blue Shield of North Carolina Senior Health depends upon contract renewal.

®, SM are marks of the Blue Cross Blue Shield Association, an association of independent Blue Cross and Blue Shield plans. All other marks and names are property of their respective owners. Blue Cross and Blue Shield of North Carolina is an independent licensee of the Blue Cross Blue Shield Association. NCBCBS-CR-058778-24-CPN57659 May 2024

Blue Cross and Blue Shield of North Carolina
 Healthy Blue + Medicare (HMO-POS D-SNP)
Clinical Criteria Updates

Effective Date	Clinical Criteria Number	Clinical Criteria Title	New or Revised
September 10, 2024	*CC-0260	Nexobrid (anacaulase-bcdb)	New
September 10, 2024	*CC-0199	Empaveli (pegcetacoplan)	Revised
September 10, 2024	*CC-0041	Complement Inhibitors	Revised
September 10, 2024	CC-0128	Tecentriq (atezolizumab)	Revised
September 10, 2024	CC-0116	Bendamustine agents	Revised
September 10, 2024	CC-0161	Sarclisa (isatuximab-irfc)	Revised
September 10, 2024	CC-0158	Enhertu (fam-trastuzumab deruxtecan-nxki)	Revised
September 10, 2024	CC-0157	Padcev (enfortumab vedotin)	Revised
September 10, 2024	CC-0230	Adstiladrin (nadofaragene firadenovec-vncg)	Revised
September 10, 2024	*CC-0125	Opdivo (nivolumab)	Revised
September 10, 2024	*CC-0119	Yervoy (ipilimumab)	Revised
September 10, 2024	*CC-0099	Abraxane (paclitaxel, protein bound)	Revised
September 10, 2024	*CC-0093	Docetaxel (Taxotere)	Revised
September 10, 2024	*CC-0094	Pemetrexed (Alimta, Pemfexy, Pemrydi)	Revised
September 10, 2024	CC-0130	Imfinzi (durvalumab)	Revised
September 10, 2024	*CC-0088	Elzonris (tagraxofusp-erzs)	Revised
September 10, 2024	*CC-0118	Radioimmunotherapy and Somatostatin Receptor Targeted Radiotherapy (Azedra, Lutathera, Pluvicto, Zevalin)	Revised
September 10, 2024	*CC-0112	Xofigo (Radium Ra 223 Dichloride)	Revised
September 10, 2024	*CC-0123	Cyramza (ramucirumab)	Revised

Blue Cross and Blue Shield of North Carolina
 Healthy Blue + Medicare (HMO-POS D-SNP)
Clinical Criteria Updates

Effective Date	Clinical Criteria Number	Clinical Criteria Title	New or Revised
September 10, 2024	*CC-0131	Besponsa (inotuzumab ozogamicin)	Revised
September 10, 2024	CC-0121	Gazyva (obinutuzumab)	Revised
September 10, 2024	CC-0122	Arzerra (ofatumumab)	Revised
September 10, 2024	CC-0232	Lunsumio (mosunetuzumab-axgb)	Revised
September 10, 2024	CC-0109	Zaltrap (ziv-aflibercept)	Revised
September 10, 2024	CC-0135	Melanoma Vaccines	Revised
September 10, 2024	*CC-0096	Asparagine Specific Enzymes	Revised
September 10, 2024	CC-0120	Kyprolis (carfilzomib)	Revised
September 10, 2024	*CC-0117	Empliciti (elotuzumab)	Revised
September 10, 2024	*CC-0126	Blinicyto (blinatumomab)	Revised
September 10, 2024	CC-0113	Sylvant (siltuximab)	Revised
September 10, 2024	CC-0132	Mylotarg (gemtuzumab ozogamicin)	Revised
September 10, 2024	CC-0097	Vidaza (azacitidine)	Revised
September 10, 2024	CC-0129	Bavencio (avelumab)	Revised
September 10, 2024	*CC-0090	Ixempra (ixabepilone)	Revised
September 10, 2024	CC-0110	Perjeta (pertuzumab)	Revised
September 10, 2024	*CC-0115	Kadcyla (ado-trastuzumab)	Revised
September 10, 2024	*CC-0108	Halaven (eribulin)	Revised
September 10, 2024	CC-0089	Mozobil (plerixafor)	Revised
September 10, 2024	CC-0124	Keytruda (pembrolizumab)	Revised

Blue Cross and Blue Shield of North Carolina
 Healthy Blue + Medicare (HMO-POS D-SNP)
Clinical Criteria Updates

Effective Date	Clinical Criteria Number	Clinical Criteria Title	New or Revised
September 10, 2024	*CC-0002	Colony Stimulating Factor Agents	Revised
September 10, 2024	*CC-0212	Tezspire (tezepelumab-ekko)	Revised
September 10, 2024	*CC-0033	Xolair (omalizumab)	Revised
September 10, 2024	*CC-0043	Monoclonal Antibodies to Interleukin-5	Revised
September 10, 2024	*CC-0029	Dupixent (dupilumab)	Revised
September 10, 2024	*CC-0208	Adbry (tralokinumab)	Revised
September 10, 2024	*CC-0062	Tumor Necrosis Factor Antagonists	Revised
September 10, 2024	*CC-0067	Prostacyclin Infusion and Inhalation Therapy	Revised
September 10, 2024	*CC-0066	Monoclonal Antibodies to Interleukin-6	Revised
September 10, 2024	*CC-0064	Interleukin-1 Inhibitors	Revised
September 10, 2024	*CC-0057	Krystexxa (pegloticase)	Revised
September 10, 2024	*CC-0068	Growth Hormones	Revised
September 10, 2024	*CC-0047	Trogarzo	Revised
September 10, 2024	*CC-0078	Orencia (abatacept)	Revised
September 10, 2024	*CC-0107	Bevacizumab for Non-ophthalmologic Indications	Revised